niftp
play

(NIFTP) Janice Bone, BS, CTR Oncology Analytics Northside Hospital - PowerPoint PPT Presentation

Sep 27, 2022 •428 likes •767 views

Introduction, Incidence and Implications of Noninvasive Follicular Thyroid Neoplasm w/Papillary Like Nuclear Features (NIFTP) Janice Bone, BS, CTR Oncology Analytics Northside Hospital Cancer Institute Objectives Review the reasons for

  1. Introduction, Incidence and Implications of Noninvasive Follicular Thyroid Neoplasm w/Papillary Like Nuclear Features (NIFTP) Janice Bone, BS, CTR Oncology Analytics Northside Hospital Cancer Institute

  2. Objectives • Review the reasons for the importance of a new histologic classification for a certain type of thyroid cancer • Understand the findings of a study that described, supported and defined NIFTP • Show the implications of NIFTP in regards to reporting, staging and treatment 2

  3. Thyroid Cancer – Incidence Source: NCI, SEER, Cancer Stat Facts: Thyroid Cancer, 2011-2015 Age Adjusted: https://seer.cancer.gov/statfacts/html/thyro.html 3

  4. Thyroid Cancer: Survival Source: NCI, SEER, Cancer Stat Facts: Thyroid Cancer: https://seer.cancer.gov/statfacts/html/thyro.html 4

  5. Concerns Regarding the Rising Incidence of Thyroid Cancer – Incidence of Thyroid cancer per SEER: • “Since early 1990s, with incidence in 2013 triple that of 30 years earlier.” – Rise of incidence of thyroid cancer due to “epidemic of diagnosis” more than “epidemic of disease” causing overdiagnosis and overtreatment. • “..intensified surveillance has resulted in an increasing incidence of early cancer with indolent behaviors, a phenomenon commonly described as cancer “overdiagnosis” • 2013-Cost of thyroid cancer care of patients estimated 1.6 billion in U.S. – Overdiagnosis/Overtreatment issues • 2009-American Thyroid Association created guidelines discouraging bx of smaller and benign looking nodules. • International panel of experts reclassified a subtype of indolent thyroid tumor to prevent overdiagnosis/overtreatment of indolent tumors. Sources: 1)NCI: After Rising for Decades, Thyroid Cancer Incidence Stabilizes. https://www.cancer.gov/news-events/cancer-currents-blog/2016/thyroid-incidence-trend 2)Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016;2(8):1023 – 1029. doi:10.1001/jamaoncol.2016.0386 5 3)Cancer Stat Facts: Thyroid Cancer: https://seer.cancer.gov/statfacts/html/thyro.html

  6. New York Times Article on NIFTP Source: New York Times Article, https://www.nytimes.com/2016/04/15/health/thyroid-tumor-cancer-reclassification.html 6

  7. Summary of New York Times Article • Based on study, a certain type of thyroid tumor that was considered cancer, is not cancer at all. • Reclassify a type of encapsulated follicular variant of papillary thyroid carcinoma(EFVPTC) to noninvasive follicular thyroid neoplasm w/papillary like nuclear features(NIFTP). • Downgraded condition will spare removal of total thyroid, tx with radioactive iodine and regular checkups for the rest of patients’ lives. • Expected to affect 10,000 - 65,000 thyroid cancer patients in the United States. Source: New York Times Article, https://www.nytimes.com/2016/04/15/health/thyroid-tumor-cancer-reclassification.html 7

  8. JAMA ONCOLOGY ARTICLE Source: Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 8 2016;2(8):1023 – 1029. doi:10.1001/jamaoncol.2016.0386

  9. Summary of Follow-up Information for Patients in Study Groups Source: Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016;2(8):1023 – 1029. doi:10.1001/jamaoncol.2016.0386 9

  10. Key Points from Study Source: Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016;2(8):1023 – 1029. doi:10.1001/jamaoncol.2016.0386 10

  11. Consensus Diagnostic Criteria for NIFTP per Study 11 Source: Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016;2(8):1023 – 1029. doi:10.1001/jamaoncol.2016.0386

  12. Summary of Results of the Study • Showed indolent nature of non-invasive EFVPTC(Grp 1 vs. Grp2) • Creation of the new consensus diagnostic criteria • Creation of the new nomenclature NIFTP – Clear distinction between non-inv EFVPTC and inv EFVPTC 12

  13. What About Treatment for NIFTP? • NCCN Guidelines – Location: https://www.nccn.org/professionals/physician_gls/default.aspx – Select NCCN Guidelines for Treatment of Cancer by Site • Select Thyroid Carcinoma – Select NCCN Guidelines PDF Source: NCCN Clinical Practice Guidelines, Thyroid Cancer NCCN Guidelines Version 1.2019, 03/28/19, NCCN.org, https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf 13

  14. Implications to Treatment for NIFTP per NCCN – Table 1 Source: NCCN Clinical Practice Guidelines, Thyroid Cancer NCCN Guidelines Version 1.2019, 03/28/19, NCCN.org, 14 https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf

  15. Implications to Treatment for NIFTP per NCCN – Table 2 Source: NCCN Clinical Practice Guidelines, Thyroid Cancer NCCN Guidelines Version 1.2019, 03/28/19, NCCN.org, 15 https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf

  16. NIFTP Discussed at NCRA 15

  17. SEER Inquiry System Question (#20160040): Reportability – Thyroid: Is a final diagnosis of "non-invasive follicular thyroid neoplasm with papillary-like nuclear features" (NIFTP) reportable when the diagnosis comment states this tumor was historically classified as encapsulated follicular variant of papillary thyroid carcinoma? See Discussion. Discussion: The term "non-invasive follicular thyroid neoplasm with papillary-like nuclear features" is now being used, instead of the previous classification of an encapsulated malignant thyroid tumor. Recent evidence supports a very minimal risk of aggressive behavior for these tumors, and pathologists in our area are no longer classifying these as malignant in the final diagnosis. Answer: Updated answer for cases diagnosed 1-1-2017 and later Report NIFTP and assign ICD-O-3 morphology code 8343/2. See NAACCR documents, pg 3. History: For cases diagnosed prior to 1-1-2017 We are discussing this terminology change with the other standard setters and with the ICD-O-3 Implementation Workgroup. When a consensus decision is made, it will be reflected in the revised MP/H (to be known as Solid Tumor) rules. For now, you can report noninvasive follicular thyroid neoplasm with papillary-like nuclear features as a synonym for encapsulated follicular variant of papillary thyroid carcinoma and assign 8340/3. Document this in a text field. 17 Source: NAACCR, http://www.naaccr.org/wp-content/uploads/2017/01/What-You-Need-to-Know-for-2017.pdf, Source: SEER Inquiry System: https://seer.cancer.gov/seerinquiry/index.php?page=view&id=20160040&type=q

  18. NAACCR: What You Need to Know for 2017, page 3 • Section 2.2 Reportability of NIFTP as a New Term for EFVPTC – Multidisciplinary international expert panel reviewed this issue and described criteria for invasive and noninvasive EFVPTC – Noninvasive EFVPC should be reported as NIFTP – NIFTP is synonym for noninvasive EFVPTC and standard setters agreed to collect NIFTP with ICD-O-3 code of 8343/2* – Standard setters have agreed to collect EFVPTC specified as invasive or NOS to 8343/3* *Histology codes are effective with cases diagnosed January 1, 2017 and forward Source: NAACCR, http://www.naaccr.org/wp-content/uploads/2017/01/What-You-Need-to-Know-for-2017.pdf 18

  19. NAACCR: What You Need to Know for 2017, Appendix B Source: NAACCR, http://www.naaccr.org/wp-content/uploads/2017/01/What-You-Need-to-Know-for-2017.pdf 19

  20. New Updated 8-22-18 Histology Table 20

  21. 8-22-18 ICD-0 3 Coding Table on Website -Link on website: https://www.naaccr.org/implementation-guidelines/#ICDO3 Source: https://www.naaccr.org/implementation-guidelines/#ICDO3 21

  22. CoC Forum Discussion regarding 8349/1 Histology Code for NIFTP Per 1/2019 COC forum post: – Discussion: NIFTP should be coded to 8349/1(per WHO blue book) since the “Physicians have explained that the term non -invasive here is not referring to in-situ, but rather describing the features of the tumor.” Per SEER : – Beginning with cases diagnosed 1/1/2017 forward, all standard setters (CoC, AJCC, NAACCR,CDC/NPCR, and SEER) agreed to report NIFTP using 8343/2. – WHO 4 th Edition Tumors of Endocrine organ has proposed 8349/1 however it has not been approved for use by standard setters. – Do not use information on Cancer Forum for reportability & histology. – Refer to Standard setter program manual for reportability & histology. Source: SEER Inquiry System-SEER Data Quality Team email 22

More recommend